The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Corontin     3,3-diphenyl-N-(1- phenylpropan-2-yl)propan...

Synonyms: Carditin, Segontin, Synadrin, Bismethin, Falliocor, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of PRENYLAMINE


High impact information on PRENYLAMINE

  • Thus, the data demonstrate that prenylamine has both tonic and use-dependent block of hNav1.5 channels similar to that of local anesthetics, but the location of the prenylamine binding site on hNav1.5 differs from that of the local anesthetic binding site [6].
  • Prenylamine block of Nav1.5 channel is mediated via a receptor distinct from that of local anesthetics [6].
  • On the other hand, binding of the CaM antagonist drugs prenylamine and calmidazolium or the potent peptide antagonist melittin did not alter MIANS fluorescence [7].
  • The 50% inhibitory concentration for prenylamine was 27.6 +/- 1.3 microm for resting channels and 0.75 +/- 0.02 microm for inactivated channels [8].
  • Furthermore, in vivo data show that 10 mm prenylamine produced a complete sciatic nerve block of motor function, proprioceptive responses, and nociceptive responses that lasted approximately 27, 34, and 24 h, respectively [8].

Chemical compound and disease context of PRENYLAMINE


Biological context of PRENYLAMINE

  • In concentrations of 10-50 microM, prenylamine significantly (P less than 0.01) shortened action potentials, and significantly (P less than 0.001) reduced the inward calcium current by 29% to 76% (n = 7) [13].
  • Heart rate was reduced by administration of only the highest dose of prenylamine [4].
  • With 2 times 10-5 M prenylamine, the steady-state sodium inactivation curve is shifted by 5 mV to more negative membrane potentials but the decreased availability of the sodium system at the resting level is not sufficient to account for the reduction of sodium current [14].
  • We have compared the cardioprotective agents prenylamine and glyceryl trinitrate (GTN) with respect to their effects on the bioenergetics of catecholamine storage vesicles [15].
  • 1 The antidysrhythmic, haemodynamic and metabolic effects of a new prospective antianginal and antidysrhythmic agent, N-(3-3-dipenylpropyl)-alpha-methyl-beta-cyclohexylethylamine hydrochloride (MG 8926), have been compared with the chemically related substance, prenylamine, in anaesthetized greyhounds and guinea-pigs [16].

Anatomical context of PRENYLAMINE


Associations of PRENYLAMINE with other chemical compounds


Gene context of PRENYLAMINE


Analytical, diagnostic and therapeutic context of PRENYLAMINE


  1. Torsade de pointes with prenylamine: do we still need the drug? Fraser, A.G., Ikram, S. Lancet (1986) [Pubmed]
  2. Prenylamine-induced contracture of frog skeletal muscle. Kirsten, E.B., Lustig, K.C. Br. J. Pharmacol. (1977) [Pubmed]
  3. Protective effect of prenylamine against vulnerability to ventricular fibrillation in the normal and ischemic canine myocardium. Schoeneberger, A.S., Verrier, R.L., Lown, B. Proc. Soc. Exp. Biol. Med. (1979) [Pubmed]
  4. The effects of verapamil, prenylamine, flunarizine and cinnarizine on coronary artery occlusion-induced arrhythmias in anaesthetized rats. Fagbemi, O., Kane, K.A., McDonald, F.M., Parratt, J.R., Rothaul, A.L. Br. J. Pharmacol. (1984) [Pubmed]
  5. Galectin-3 stimulates uptake of extracellular Ca2+ in human Jurkat T-cells. Dong, S., Hughes, R.C. FEBS Lett. (1996) [Pubmed]
  6. Prenylamine block of Nav1.5 channel is mediated via a receptor distinct from that of local anesthetics. Mujtaba, M.G., Wang, S.Y., Wang, G.K. Mol. Pharmacol. (2002) [Pubmed]
  7. Biologically active fluorescent derivatives of spinach calmodulin that report calmodulin target protein binding. Mills, J.S., Walsh, M.P., Nemcek, K., Johnson, J.D. Biochemistry (1988) [Pubmed]
  8. Local anesthetic properties of prenylamine. Mujtaba, M.G., Gerner, P., Wang, G.K. Anesthesiology (2001) [Pubmed]
  9. Torsade de pointes due to prenylamine controlled by lignocaine. Tamari, I., Rabinowitz, B., Neufeld, H.N. Eur. Heart J. (1982) [Pubmed]
  10. Amelioration of adriamycin-induced cardiotoxicity in rabbits by prenylamine and vitamins A and E. Milei, J., Boveris, A., Llesuy, S., Molina, H.A., Storino, R., Ortega, D., Milei, S.E. Am. Heart J. (1986) [Pubmed]
  11. Mechanisms underlying the hemolytic and ichthyotoxic activities of maitotoxin. Igarashi, T., Aritake, S., Yasumoto, T. Nat. Toxins (1999) [Pubmed]
  12. Effects of prenylamine and AQ-A 39 on reentrant ventricular arrhythmias induced during the late myocardial infarction period in conscious dogs. Aidonidis, I., Egel, E., Hilbel, T., Kuebler, W., Brachmann, J. J. Cardiovasc. Pharmacol. (1993) [Pubmed]
  13. The effects of prenylamine on single ventricular myocytes of guinea-pig. Shimoni, Y., Posner, P., Spindler, A.J., Noble, D. Br. J. Pharmacol. (1988) [Pubmed]
  14. Effects of prenylamine on cardiac membrane currents and contractility. Haas, H.G., Kern, R., Benninger, C., Einwächter, H.M. J. Pharmacol. Exp. Ther. (1975) [Pubmed]
  15. The effect of prenylamine and organic nitrates on the bioenergetics of bovine catecholamine storage vesicles. Grønberg, M., Terland, O., Husebye, E.S., Flatmark, T. Biochem. Pharmacol. (1990) [Pubmed]
  16. The haemodynamic and metabolic effects of MG 8926, a prospective antidysrhythmic and antianginal agent. Marshall, R.J., Parratt, J.R. Br. J. Pharmacol. (1977) [Pubmed]
  17. Effects of various calmodulin antagonists on contraction of rabbit aortic strips. Asano, M., Suzuki, Y., Hidaka, H. J. Pharmacol. Exp. Ther. (1982) [Pubmed]
  18. Stimulation of canine cardiac sarcoplasmic reticulum Ca2+ uptake by dihydropyridine Ca2+ antagonists. Movsesian, M.A., Ambudkar, I.S., Adelstein, R.S., Shamoo, A.E. Biochem. Pharmacol. (1985) [Pubmed]
  19. Localization of a felodipine (dihydropyridine) binding site on calmodulin. Johnson, J.D., Wittenauer, L.A., Thulin, E., Forsén, S., Vogel, H.J. Biochemistry (1986) [Pubmed]
  20. The pharmacological properties of the peptide, endothelin. Eglen, R.M., Michel, A.D., Sharif, N.A., Swank, S.R., Whiting, R.L. Br. J. Pharmacol. (1989) [Pubmed]
  21. Inactivation of glibenclamide-sensitive K+ channels in Xenopus oocytes by various calmodulin antagonists. Sakuta, H., Sekiguchi, M., Okamoto, K., Sakai, Y. Eur. J. Pharmacol. (1992) [Pubmed]
  22. Effects of some antianginal and vasodilating drugs on sodium influx and on the binding of 3H-batrachotoxinin-A 20-alpha-benzoate and 3H-tetracaine. Velly, J., Grima, M., Marciniak, G., Spach, M.O., Schwartz, J. Naunyn Schmiedebergs Arch. Pharmacol. (1987) [Pubmed]
  23. Effect of phentolamine, alprenolol and prenylamine on maximum rate of rise of action potential in guinea-pig papillary muscles. Sada, H. Naunyn Schmiedebergs Arch. Pharmacol. (1978) [Pubmed]
  24. Slow calcium channel blockers and calmodulin. Effect of felodipine, nifedipine, prenylamine and bepridil on cardiac sarcolemmal calcium pumping ATPase. Lamers, J.M., Cysouw, K.J., Verdouw, P.D. Biochem. Pharmacol. (1985) [Pubmed]
  25. Characteristics of the inhibitory effect of calmodulin on specific [125i]omega-conotoxin GVIA binding to crude membranes from chick brain. Ichida, S., Abe, J., Zhang, Y.A., Sugihara, K., Imoto, K., Wada, T., Fujita, N., Sohma, H. Neurochem. Res. (2000) [Pubmed]
  26. Interaction of calmodulin and calcium antagonists with [3H]diltiazem and [3H]nitrendipine binding sites. Schaeffer, P., Lugnier, C., Stoclet, J.C. J. Cardiovasc. Pharmacol. (1988) [Pubmed]
  27. The role of prenylamine in the prevention of adriamycin-induced cardiotoxicity. A review of experimental and clinical findings. Milei, J., Vazquez, A., Boveris, A., Llesuy, S., Molina, H.A., Storino, R., Marantz, A. J. Int. Med. Res. (1988) [Pubmed]
  28. In vitro and in vivo characterization of a calcium modulator of the diphenylalkylamine type with selective coronary dilatory properties. Caldirola, P., Monteil, A., Zandberg, P., Mannhold, R., Timmerman, H. Arzneimittel-Forschung. (1997) [Pubmed]
  29. Effects of prenylamine on transmembrane action potentials as related to the change in external potassium concentrations in guinea pig papillary muscle. Ban, T., Kojima, M., Sada, H., Oshita, S. J. Cardiovasc. Pharmacol. (1982) [Pubmed]
  30. Prenylamine and the myocardial response to ischaemia and reperfusion: effects of acute and chronic treatment. Manning, A.S., Shattock, M.J., Hearse, D.J. J. Pharm. Pharmacol. (1982) [Pubmed]
  31. Amphetamine concentrations in human urine following single-dose administration of the calcium antagonist prenylamine-studies using fluorescence polarization immunoassay (FPIA) and GC-MS. Kraemer, T., Roditis, S.K., Peters, F.T., Maurer, H.H. Journal of analytical toxicology. (2003) [Pubmed]
WikiGenes - Universities